Chart — Renal · Pharmacology
Nephrotoxic Drugs Reference Chart
Quick-reference comparison of major nephrotoxic drug classes — NSAIDs, aminoglycosides, iodinated contrast, ACE inhibitors/ARBs, vancomycin, cisplatin, and calcineurin inhibitors. Mechanism, injury type, risk factors, monitoring parameters, prevention strategies, and nursing notes in one chart.
Chart · Renal · Pharmacology
Educational use only. Drug monitoring parameters and dosing adjustments are institution-specific. Always consult pharmacy for CKD dosing. The nurse's role: recognize risk, monitor creatinine/UO, and communicate early. This material supports nursing education and exam review. It is not medical advice and is not a substitute for clinical judgment, institutional policy, or medical direction. Always follow facility protocols and current provider orders.
High-Risk Combinations to Recognize Immediately:
- NSAIDs + ACE/ARB + diuretic = "Triple Whammy" AKI
- Aminoglycoside + vancomycin = very high nephrotoxicity risk
- Aminoglycoside + furosemide = additive nephrotoxicity + ototoxicity
- ACE/ARB + bilateral renal artery stenosis = CONTRAINDICATED (acute AKI)
- Contrast + dehydration + CKD = high CIN risk — pre-hydrate first
NSAIDs
Examples: Ibuprofen, naproxen, ketorolac (Toradol), indomethacin, celecoxib
Injury: Prerenal / Interstitial
| Mechanism | Inhibit prostaglandins → afferent arteriolar constriction → decreased GFR → prerenal AKI. Chronic use: interstitial nephritis, analgesic nephropathy. |
| Risk Factors | Volume depletion, age > 65, CKD, CHF, cirrhosis, concurrent ACE/ARB + diuretics ('triple whammy') |
| Monitoring | BUN/Cr at baseline and 3–7 days. Urine output. Signs of fluid retention. |
| Prevention | Ensure hydration. Avoid in high-risk patients. Shortest effective dose. Prefer acetaminophen. |
| Nursing Notes | Teach patients: OTC NSAIDs dangerous in CKD. Never combine with ACE/ARBs and diuretics. Hold before contrast procedures. |
| NCLEX Pearl | NSAIDs + ACE/ARB + diuretic = 'triple whammy' AKI. Contraindicated in CKD Stage 4+. |
Aminoglycosides
Examples: Gentamicin, tobramycin, amikacin, streptomycin
Injury: Intrarenal — ATN
| Mechanism | Accumulate in proximal tubular cells → free radical generation → tubular cell necrosis → ATN. Concentration-dependent and cumulative toxicity. |
| Risk Factors | Volume depletion, age, CKD, prolonged therapy > 5 days, concurrent vancomycin or furosemide, high cumulative dose, multiple daily dosing |
| Monitoring | Peak (30–60 min post-infusion) and trough (before next dose). BUN/Cr q2–3 days. Urine output. Also monitor for ototoxicity (hearing, vestibular function). |
| Prevention | Extended-interval (once-daily) dosing. Adequate hydration. Avoid concurrent nephrotoxins. Shortest course. Level monitoring. |
| Nursing Notes | Trough drawn BEFORE dose; peak drawn 30–60 min AFTER infusion (per protocol). Infuse over 30–60 min (not bolus). Monitor hearing. Report rising Cr or falling UO immediately. |
| NCLEX Pearl | Trough = BEFORE dose; peak = 30–60 min AFTER infusion. Both nephrotoxic AND ototoxic. Extended-interval dosing (q24h) reduces nephrotoxicity. |
Iodinated Contrast
Examples: IV contrast for CT scans, cardiac catheterization, angiography, myelography
Injury: Intrarenal — ATN
| Mechanism | Direct tubular toxicity + renal vasoconstriction → tubular ischemia → ATN (contrast-induced nephropathy/CIN). Onset 24–48h, peak Cr at 3–5 days, typically resolves 7–10 days. |
| Risk Factors | CKD (eGFR < 60 significant; < 30 high risk), diabetes, dehydration, high contrast volume, multiple exposures, concurrent NSAIDs/nephrotoxins |
| Monitoring | Baseline BUN/Cr + eGFR before procedure. Cr at 24–48h and 3–5 days post-contrast. Urine output post-procedure. |
| Prevention | IV NS 0.9% hydration (most evidence-based): 1 mL/kg/hr 3–12h before + 6–12h after. Low-osmolality or iso-osmolality contrast. Minimize volume. Hold NSAIDs. N-acetylcysteine (controversial). Hold metformin if eGFR < 60 (stop at the time of/just before contrast, then withhold 48h after and recheck renal function). |
| Nursing Notes | Confirm eGFR before procedure. Ensure pre-hydration running. Hold metformin if ordered. Post-procedure: monitor UO and Cr. Patient should not be NPO without hydration compensation. |
| NCLEX Pearl | IV saline hydration = most effective CIN prevention. Hold metformin before/after contrast in CKD (lactic acidosis risk). Cr peaks 3–5 days post-contrast. Gadolinium MRI contrast causes NSF in eGFR < 30 — avoid. |
ACE Inhibitors / ARBs
Examples: ACE-I: lisinopril, enalapril, ramipril. ARBs: losartan, valsartan, irbesartan
Injury: Prerenal (hemodynamic)
| Mechanism | Block angiotensin II → efferent arteriole dilation → reduced intraglomerular pressure. AKI risk when afferent + efferent vasodilation occurs (NSAIDs block afferent dilation + ACE/ARB blocks efferent constriction). |
| Risk Factors | Volume depletion, concurrent NSAIDs or diuretics, bilateral renal artery stenosis (CONTRAINDICATED), dehydration |
| Monitoring | Creatinine and K⁺ at 1–2 weeks after initiating and with dose increases. Creatinine rise up to 30% above baseline acceptable. > 30% = stop and evaluate. |
| Prevention | Ensure hydration before initiating. Avoid concurrent NSAIDs. Contraindicated in bilateral renal artery stenosis. |
| Nursing Notes | Teach: never stop without provider guidance. Monitor K⁺ (hyperkalemia risk). Report Cr rise > 30%. ACE-I: dry cough → switch to ARB (not stop entirely). ACE-I angioedema = emergency (tongue/throat swelling → epinephrine). |
| NCLEX Pearl | Bilateral renal artery stenosis + ACE/ARB = CONTRAINDICATED (acute life-threatening AKI). Acceptable Cr rise: up to 30% (hemodynamic, not structural). Hyperkalemia is expected side effect. |
Vancomycin
Examples: Vancomycin IV (glycopeptide antibiotic for MRSA, gram-positive infections)
Injury: Intrarenal — Tubular
| Mechanism | Mechanism unclear: oxidative stress and direct tubular toxicity. Dramatically increased when combined with aminoglycosides or piperacillin-tazobactam. |
| Risk Factors | High trough levels, concurrent aminoglycosides or pip-tazo (highest risk), prolonged therapy, CKD, volume depletion, ICU, obesity |
| Monitoring | AUC/MIC-based monitoring (target AUC 400–600 mg·h/L). Daily Cr in high-risk patients. Urine output. |
| Prevention | AUC-based dosing. Avoid concurrent aminoglycosides. Limit pip-tazo combination when possible. Maintain hydration. |
| Nursing Notes | Infuse over ≥ 60 min (1g) or longer — rapid infusion causes Red Man Syndrome (not allergy — histamine release). Report rising Cr. AUC monitoring requires timed levels — coordinate with pharmacy. |
| NCLEX Pearl | Red Man Syndrome (flushing, hypotension) ≠ allergy → slow infusion rate. Vancomycin + aminoglycoside = very high nephrotoxicity risk. AUC monitoring is current standard (not just trough). |
Cisplatin
Examples: Cisplatin (cis-DDP); carboplatin is less nephrotoxic
Injury: Intrarenal — ATN + Mg wasting
| Mechanism | Accumulates in proximal tubular cells → DNA crosslinking → oxidative stress → tubular necrosis. Also causes profound magnesium wasting (tubular damage disrupts Mg reabsorption). |
| Risk Factors | Cumulative dose (dose-dependent), CKD, dehydration, concurrent nephrotoxins, age, repeated cycles |
| Monitoring | BUN/Cr and eGFR before each cycle. Electrolytes (Mg, K, Ca, Phos). Urine output during infusion (maintain > 100 mL/hr). Cumulative dose tracking. |
| Prevention | Aggressive IV NS hydration before and after (standard protocol). Forced diuresis (mannitol or furosemide in some protocols). Mg replacement. Amifostine (cytoprotectant — used in some protocols). |
| Nursing Notes | Administer pre-hydration exactly per order (typically 1–2L NS before cisplatin). Target UO > 100 mL/hr during infusion. Aggressive Mg replacement post-cisplatin (can cause severe hypomagnesemia). Monitor for ototoxicity simultaneously. |
| NCLEX Pearl | Cisplatin = nephrotoxic AND ototoxic. Pre-hydration + forced diuresis required. Causes hypomagnesemia (replace aggressively). Monitor Cr before each chemotherapy cycle. |
Calcineurin Inhibitors
Examples: Tacrolimus (FK506, Prograf), Cyclosporine (Sandimmune, Neoral)
Injury: Prerenal (acute) / Interstitial fibrosis (chronic)
| Mechanism | Afferent arteriolar vasoconstriction → reduced GFR (acute). Long-term: progressive interstitial fibrosis and tubular atrophy → chronic calcineurin inhibitor nephropathy (irreversible). |
| Risk Factors | Supratherapeutic drug levels, dehydration, concurrent NSAIDs or ACE/ARBs, duration of use, grapefruit ingestion (raises levels) |
| Monitoring | Whole blood trough levels (before AM dose). Tacrolimus target: 5–15 ng/mL (varies by time post-transplant and protocol). Cr q1–3 months. BP (both drugs cause hypertension). |
| Prevention | Target minimum effective immunosuppressive levels. Avoid hypovolemia. Regular level monitoring. Avoid grapefruit (CYP3A4 inhibitor → supratherapeutic levels). |
| Nursing Notes | Trough levels drawn BEFORE morning dose. Same time every day (consistent absorption). No grapefruit. Report creatinine rise or decreased UO in transplant patient immediately — distinguish rejection vs drug toxicity (biopsy needed). Both cause HTN, hyperkalemia, hyperglycemia, neurotoxicity. |
| NCLEX Pearl | Tacrolimus trough = before AM dose. No grapefruit. Rising Cr in transplant = rejection vs toxicity (need biopsy). Calcineurin inhibitors cause HTN, hyperkalemia, nephrotoxicity, neurotoxicity. |
Universal Nephrotoxicity Prevention Principles
Hydration is the most effective prevention for most nephrotoxic agents — especially contrast, aminoglycosides, cisplatin.
Check eGFR before administering nephrotoxic drugs. Alert provider if eGFR is reduced.
Monitor creatinine daily in high-risk patients on nephrotoxic agents. KDIGO AKI Stage 1 = Cr rise ≥ 0.3 mg/dL in 48h — act early.
Never silently accept a rising creatinine. Report any upward trend to the prescriber immediately.
Aminoglycoside trough = before dose; peak = 30–60 min after infusion. AUC monitoring for vancomycin is current standard.
Tacrolimus trough = before AM dose. No grapefruit. Same time every day for consistent levels.
Related Resources
Standards & sources
Fact-checked Jun 21, 2026This page is written to align with KDIGO Clinical Practice Guidelines · National Kidney Foundation (NKF). It is an educational summary, not a citation of any single document — always verify specific doses, values, and protocols against current guidelines and your facility policy. How we source content →